Dr Satya Brahma’s Post

The Inflation Reduction Act (IRA) is set to transform U.S. healthcare, particularly in how prescription drugs are priced. Here's a snapshot of what healthcare professionals need to know: 🔷 Balancing Act - The IRA aims to lower drug prices to increase patient access without stifling pharmaceutical innovation—a delicate balance with implications for future drug development. 🔷 Challenges Ahead - Implementation has sparked debate, especially around the potential impact on investments in therapies and research, highlighting concerns over innovation in the aging population's diseases. 🔷 The Bigger Picture - Beyond drug pricing, the IRA catalyzes a broader examination of the U.S. healthcare system, emphasizing the need for comprehensive reform across all cost drivers. Reflections for Healthcare Industry - 🔷 Can the IRA create a sustainable model that supports both innovation and affordability? 🔷 How can collaboration between the government and the pharma industry lead to positive societal change in healthcare? #HealthcareReform #DrugPricing #IRA #PharmaceuticalInnovation

🔴 Live | #PraxInsightsOnBudget by Garima Malhotra, Associate Partner – Healthcare, Praxis Global Alliance. In the #UnionBudget 2024-25 tabled yesterday, #FM Nirmala Sitharaman proposed to completely exempt three major cancer medicines from basic customs duties. Various programs in the #healthcare, #pharmaceuticals, and #medical devices segments were also announced. 🏥Focus on reducing medicine costs and supporting the domestic pharma industry. 🏥₹85,000 crore allocation to boost public health infrastructure and pharma research. 🏥Increased support for pharmaceutical research to drive innovation and competitiveness. 🏥Encourages advancements in healthcare delivery and access to essential medicines. These measures show the government's commitment to making healthcare more accessible and affordable for all citizens. Stay tuned with Praxis Global Alliance for key #Budget2024 highlights across various #sectors. #Budget2024 #SuperiorOutcomes

Our SVP of Supply Chain Management, Sugeet Chopra, recently participated in a high-impact panel discussion on "How Logistics Can Help India Pharma Deliver Affordable Medicines Globally" at the Global Pharma Logistics Summit 2024 in Mumbai. The event brought together key industry leaders under one roof to explore innovative solutions for global healthcare. Sugeet highlighted the crucial role of compliance at Strides and shared valuable insights into strategies that can enhance logistics, making affordable medicine delivery more accessible worldwide. His insights not only underscored our dedication to global healthcare but also sparked meaningful conversations about the future of pharmaceutical logistics. #Strides #GlobalHealthcare #PharmaLogistics #MedicineBeyondBorders #GlobalPharmaLogisticsSummit

🔍 PRICING STRATEGY: THE HEART OF THE PHARMACEUTICAL BUSINESS This month's PRiMA Headlines delves into the crucial topic of pricing strategy in the Pharma industry. Authored by Chris Shilling, our Opinion piece sheds light on the growing significance of pricing strategy amidst challenges in demonstrating value. The full article is exclusively available to our PRiMA Headlines Pro subscribers. Other key highlights include: - BeNeLuxA's groundbreaking cross-country procurement deal with Orchard for Libmeldy, the most expensive drug. - Italy's AIFA streamlining pricing and reimbursement processes. - Inflation-driven product withdrawals in Türkiye. - Significant systematic review of medicines access across Africa and the impact of Covid19-related procurement changes. 💹 One of the most exciting aspects of our specialization in emerging markets is guiding companies towards achieving win-win-win outcomes for patients, payers, and the industry. 📢 Stay informed with PRiMA Headlines! Subscribe for the free reduced version or express your interest in accessing the Pro version, complete with the Opinion piece, 99 curated stories, and our comprehensive searchable database covering over 8000 stories from 150 countries since 2015. Save time and stay confident by staying informed with PRiMA Headlines! 🖱 Get the free version immediately by subscribing here: https://lnkd.in/dN4Gs42B 🖱 Click here to request the Pro version: https://lnkd.in/dtUGkRSf #PharmaUpdates #PRiMA #PRiMAHeadlines 

Just 4 weeks until CAHR's #MarketAccessForum, we invite you to register and join us on Thursday, October 10, for a full day of engaging discussions. This event is designed to significantly enhance your knowledge and provide valuable networking opportunities that will connect you with industry peers. #MarketAccessForum (MAF) delivers multifaceted insights into current issues, key topics and health care policy of paramount importance to the pharmaceutical industry and its various stakeholders. It provides attendees with context and insight to better understand the issues facing market access professionals. It's your chance to delve into critical issues impacting the market access arena and boost your professional growth. You will hear about: ↗ CDA Changes & Innovations in HTAs ↗ QC – Santé Québec ↗ Drug #Shortages ↗ Innovations in the Private Payer Space ↗ OBA —Innovative Agreements ↗ Innovation in Access For more information or to register, visit: https://shorturl.at/K9gXJ

🌟 Exciting insights from our CEO Jenny Ousbey who spoke at the Patient Centricity & Collaboration World Congress earlier this week! 🌍 At the event, Emma Sutcliffe spearheaded a theme of #noexcuses for progress. In that spirit, here are Jenny's six compelling reasons why patient advocacy and engagement are essential for pharmaceutical companies: 1️⃣ Patient engagement boosts participation in clinical trials and improves medicine adherence. 2️⃣ 81% of FDA approvals in 2019 relied on relevant patient experience data. 3️⃣ Engaging patients pre-launch can trim product time to market by 2.5 years. 4️⃣ 90% of doctors equate patient engagement with data, emphasizing the need for further progress. 5️⃣ Investors are increasingly prioritizing patient centricity and engagement in discussions with executives. 6️⃣ Yet, only a few companies have a Chief Patient Officer on their leadership team, indicating room for improvement. As Leonard Kish noted, patient engagement is the blockbuster drug of the century. Let's rally behind it! 💪 Join the movement by participating in the Patient Partnership Index at https://lnkd.in/esSzZQMc. The Association of the British Pharmaceutical Industry (ABPI) Healthcare Communications Association (HCA) #PatientCentricity #Pharmaceuticals #NoExcuses #Leadership

📣 Why should the pharmaceutical industry care about pathway innovation? Welcome to the fourth instalment in TCC Health's Spotlight Series. Introducing our Chief Executive Officer, Sangeeta Patil. Sangeeta has experience from both in-house and consultancy, so she knows first hand how tough it can be to bring innovative solutions to the healthcare system. Sangeeta has worked extensively with global pharma to solve pathway challenges which improve access to treatment and optimise care across therapy areas. With that in mind, we asked her: Why should pharma care about pathway innovation? See what she answered below 👇 #pharmainnovation #innovationconsultancy #pathwayinnovation #healthcareinnovation #pharmastrategy

🌐 Join the MPP Association and lead the future of health innovation 🌐 The Medtech & Pharma Platform Association brings together key companies across the pharmaceutical, medtech, and diagnostic sectors that are actively working on developing and improving access to combined products. Here’s how MPP membership empowers you to make an impact: 🔹 Policy dialogue: Contribute to working groups and engage with regulators to proactively shape future healthcare policy & regulation 🔹 Insights: Stay ahead with updates on policy changes impacting combined products 🔹 Networking: Connect with key stakeholders to drive innovative healthcare solutions 🔹 Access to expertise: Benefit from a network and a robust knowledge pool for combined products 🔹 Membership benefits: Enjoy reduced rates at the MPP Annual Conference and access to other events 📈 Join us to shape tomorrow's health solutions: https://bit.ly/3KGx1hz #CombinedProducts #Pharma #Medtech #IVDs

Exciting developments are underway in Spain's healthcare sector as a more systematic approach to pharmaceutical evaluation and decision-making is being introduced. The upcoming implementation of the new Royal Decree on Health Technology Assessment promises a structured three-tier model, ensuring clarity and separation between evaluation, positioning, and decision phases. This innovative framework aims to streamline the processes and enhance transparency in healthcare decisions. In a parallel stride, the Health and Social Consortium of Catalonia, in collaboration with Lyfegen, is pioneering new value-based purchasing models. This initiative not only underscores Spain's commitment to progressive healthcare strategies but also leverages real-world data to ensure cost-effectiveness and patient-centric care. These advancements signify a pivotal transformation in managing healthcare evaluations and pharmaceutical pricing, promising better outcomes for all stakeholders involved. Learn more about the new assessment system (Spanish): https://lnkd.in/dtGENv2f Read our press release here: https://lnkd.in/dnnXjtWS Thank you for your inspiring coverage Neil Grubert. #HealthcareInnovation #ValueBasedHealthcare #SpanishHealthcare

💵 Sanofi in talks to sell 50% stake in consumer health business to CD&R💵 Sanofi (SASY.PA),has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said on Friday. The announcement confirms an earlier Reuters report that it was closing in on a sale estimated at around 15 billion euros ($16.41 billion). Sanofi did not disclose any financial details of the potential deal, and said further updates would be provided in due course. Shares in the group were down 0.46% at 0717 GMT. The French finance ministry said in a statement that CD&R was a "serious investment fund" with positive prospects for Opella's development and its plants in France. It added that it would require economic commitments from Sanofi and CD&R including guaranteeing that the business's headquarters and decision-making centres would remain in France, and protection of its industrial footprint in the country. "This proposed sale does not call into question the production in France of Doliprane or other essential medicines produced by Opella on our territory, nor the supply of these medicines to the market. This is naturally part of the commitments requested," it added. Rival Johnson & Johnson (JNJ.N), hived off its consumer health business Kenvue (KVUE.N), in May last year, while GSK (GSK.L), and Pfizer (PFE.N)  spun off their consumer divisions in 2022.